Jacobs Levy Equity Management’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $597K | Sell |
429,669
-228,143
| -35% | -$314K | ﹤0.01% | 793 |
|
|
2025
Q4 | $1.06M | Sell |
657,812
-4,718
| -0.7% | -$9.88K | ﹤0.01% | 673 |
|
|
2025
Q3 | $1.81M | Sell |
662,530
-542,598
| -45% | -$1.81M | 0.01% | 610 |
|
|
2025
Q2 | $4.39M | Sell |
1,205,128
-374,227
| -24% | -$1.03M | 0.02% | 463 |
|
|
2025
Q1 | $3.03M | Buy |
1,579,355
+350,645
| +29% | +$716K | 0.01% | 568 |
|
|
2024
Q4 | $2.33M | Sell |
1,228,710
-805,459
| -40% | -$1.4M | 0.01% | 568 |
|
|
2024
Q3 | $2.69M | Sell |
2,034,169
-60,564
| -3% | -$80.9K | 0.01% | 546 |
|
|
2024
Q2 | $2.14M | Buy |
2,094,733
+457,155
| +28% | +$565K | 0.01% | 587 |
|
|
2024
Q1 | $3M | Sell |
1,637,578
-219,347
| -12% | -$351K | 0.01% | 525 |
|
|
2023
Q4 | $2.3M | Buy |
1,856,925
+137,864
| +8% | +$141K | 0.01% | 579 |
|
|
2023
Q3 | $1.96M | Buy |
1,719,061
+373,029
| +28% | +$479K | 0.01% | 556 |
|
|
2023
Q2 | $1.23M | Buy |
1,346,032
+147,308
| +12% | +$142K | 0.01% | 659 |
|
|
2023
Q1 | $672K | Sell |
1,198,724
-816,043
| -41% | -$623K | ﹤0.01% | 763 |
|
|
2022
Q4 | $1.16M | Sell |
2,014,767
-28,049
| -1% | -$8.79K | 0.01% | 658 |
|
|
2022
Q3 | $646K | Buy |
2,042,816
+1,265,199
| +163% | +$496K | 0.01% | 792 |
|
|
2022
Q2 | $275K | Sell |
777,617
-207,124
| -21% | -$86.9K | ﹤0.01% | 936 |
|
|
2022
Q1 | $707K | Sell |
984,741
-1,753,159
| -64% | -$3.75M | ﹤0.01% | 811 |
|
|
2021
Q4 | $6.19M | Buy |
2,737,900
+75,855
| +3% | +$207K | 0.04% | 389 |
|
|
2021
Q3 | $7.67M | Sell |
2,662,045
-245,289
| -8% | -$700K | 0.05% | 354 |
|
|
2021
Q2 | $11M | Buy |
2,907,334
+239,305
| +9% | +$806K | 0.07% | 274 |
|
|
2021
Q1 | $9.03M | Buy |
2,668,029
+673,177
| +34% | +$2.42M | 0.07% | 305 |
|
|
2020
Q4 | $5.59M | Buy |
1,994,852
+1,296,947
| +186% | +$3.79M | 0.05% | 375 |
|
|
2020
Q3 | $1.75M | Buy |
697,905
+230,762
| +49% | +$2.02M | 0.02% | 541 |
|
|
2020
Q2 | $6.34M | Sell |
467,143
-30,615
| -6% | -$317K | 0.07% | 298 |
|
|
2020
Q1 | $3.77M | Buy |
497,758
+136,125
| +38% | +$1.06M | 0.05% | 349 |
|
|
2019
Q4 | $2.29M | Buy |
+361,633
| New | +$1.72M | 0.02% | 520 |
|
|
2019
Q3 | – | Sell |
-152,461
| Closed | -$738K | – | 912 |
|
|
2019
Q2 | $738K | Sell |
152,461
-485,099
| -76% | -$2.76M | 0.01% | 685 |
|
|
2019
Q1 | $5.22M | Buy |
637,560
+222,708
| +54% | +$1.53M | 0.08% | 324 |
|
|
2018
Q4 | $2.29M | Buy |
414,852
+84,400
| +26% | +$660K | 0.04% | 431 |
|
|
2018
Q3 | $2.92M | Buy |
330,452
+54,299
| +20% | +$486K | 0.04% | 432 |
|
|
2018
Q2 | $2.76M | Buy |
276,153
+192,834
| +231% | +$1.93M | 0.04% | 435 |
|
|
2018
Q1 | $794K | Buy |
83,319
+46,909
| +129% | +$656K | 0.01% | 686 |
|
|
2017
Q4 | $541K | Buy |
36,410
+14,620
| +67% | +$242K | 0.01% | 737 |
|
|
2017
Q3 | $429K | Buy |
21,790
+2,310
| +12% | +$35.5K | 0.01% | 730 |
|
|
2017
Q2 | $280K | Buy |
+19,480
| New | +$247K | 0.01% | 781 |
|
|
2016
Q3 | – | Sell |
-16,465
| Closed | -$123K | – | 1006 |
|
|
2016
Q2 | $123K | Buy |
+16,465
| New | +$144K | ﹤0.01% | 1073 |
|
Other funds holding AKBA
VCM
VPM
Jacobs Levy Equity Management's AKBA Position: Q1 2026 in Review
Jacobs Levy Equity Management reduced its Akebia Therapeutics (AKBA) stake by 35% in Q1 2026, selling an estimated $314K and leaving 429,669 shares worth $597K. The position accounts for ﹤0.01% of the portfolio, ranked #793.
Jacobs Levy Equity Management first reported a position in AKBA in Q2 2016 and has held it in 36 quarters since. The position peaked at $11M in Q2 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Jacobs Levy Equity Management held 429,669 shares of Akebia Therapeutics worth $597K as of Q1 2026.
- Jacobs Levy Equity Management sold 228,143 Akebia Therapeutics shares in Q1 2026, an estimated $314K.
- Akebia Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #793 holding.
- Jacobs Levy Equity Management first reported a position in Akebia Therapeutics in Q2 2016 and has held it in 36 quarters since.
- Jacobs Levy Equity Management's Akebia Therapeutics position peaked at $11M in Q2 2021.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.